Xeris Biopharma Holdings (XERS) Cash from Operations Growth (3y) (2023 - 2026)
Xeris Biopharma Holdings (XERS) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.78 Bn | 87.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.02 Bn | 32.28 Bn | 1.97 Bn | 34.90% |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | -9.94% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -10.80% |
| 5 | United Therapeutics | 23.09 Bn | 20.94 Bn | 648.10 Mn | 7.32% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.35 Bn | 18.54 Bn | 1.16 Bn | -26.33% |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn | 46.81% |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | 27.85% |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | 33.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 33.47% |
| Dec 31, 2025 | 48.03% |
| Sep 30, 2025 | 44.83% |
| Jun 30, 2025 | 26.18% |
| Mar 31, 2025 | 40.82% |
| Dec 31, 2024 | 27.41% |
| Sep 30, 2024 | 28.38% |
| Jun 30, 2024 | 19.75% |
| Mar 31, 2024 | 5.37% |
| Dec 31, 2023 | 39.03% |